Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
$8.62
+1.2%
$5.33
$1.92
$11.60
$449.55M2.41604,251 shs601,060 shs
Precigen, Inc. stock logo
PGEN
Precigen
$1.91
+6.1%
$1.64
$0.65
$2.17
$531.32M1.873.05 million shs4.54 million shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$1.61
-1.8%
$1.49
$0.82
$3.10
$128.17M-0.21846,585 shs936,917 shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.75
+1.4%
$18.24
$13.30
$25.00
$422.30M1.122,010 shs13,846 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
+1.17%+4.99%+66.73%+158.86%+229.01%
Precigen, Inc. stock logo
PGEN
Precigen
+6.11%+4.37%-2.05%+45.80%+75.23%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
-1.83%+8.78%+13.38%-3.59%+54.81%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
-1.55%-2.50%+1.08%+8.00%-22.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.5952 of 5 stars
1.01.00.04.63.33.30.0
Precigen, Inc. stock logo
PGEN
Precigen
4.0869 of 5 stars
3.51.00.04.73.11.70.6
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.6253 of 5 stars
3.53.00.00.03.41.71.9
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
2.1533 of 5 stars
3.83.00.00.02.70.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
2.00
Hold$9.004.41% Upside
Precigen, Inc. stock logo
PGEN
Precigen
3.00
Buy$6.00214.14% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$15.00831.68% Upside
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
3.50
Strong Buy$45.00153.59% Upside

Current Analyst Ratings Breakdown

Latest PLX, KOD, PGEN, and PRTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
6/12/2025
Precigen, Inc. stock logo
PGEN
Precigen
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$6.00
5/15/2025
Precigen, Inc. stock logo
PGEN
Precigen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/A$2.86 per shareN/A
Precigen, Inc. stock logo
PGEN
Precigen
$3.92M143.82N/AN/A$0.13 per share14.69
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$59.76M2.14$0.09 per share17.80$0.47 per share3.43
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.83M88.65$2.47 per share7.19$17.04 per share1.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)
Precigen, Inc. stock logo
PGEN
Precigen
-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.04N/A5.19N/A-21.03%-30.89%-11.74%N/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$27.78MN/A0.00N/AN/AN/AN/AN/A8/28/2025 (Estimated)

Latest PLX, KOD, PGEN, and PRTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$1.01-$1.03-$0.02-$1.03N/AN/A
8/12/2025Q2 2025
Precigen, Inc. stock logo
PGEN
Precigen
-$0.14-$0.11+$0.03-$0.09$0.67 million$0.86 million
5/14/2025Q1 2025
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
-$0.89-$1.09-$0.20-$1.09N/AN/A
5/14/2025Q1 2025
Precigen, Inc. stock logo
PGEN
Precigen
-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
N/A
4.62
4.62
Precigen, Inc. stock logo
PGEN
Precigen
N/A
3.53
3.53
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
9.33
9.33

Institutional Ownership

CompanyInstitutional Ownership
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
89.06%
Precigen, Inc. stock logo
PGEN
Precigen
33.51%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%

Insider Ownership

CompanyInsider Ownership
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
45.90%
Precigen, Inc. stock logo
PGEN
Precigen
47.10%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.50%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Kodiak Sciences Inc. stock logo
KOD
Kodiak Sciences
9052.76 million28.55 millionOptionable
Precigen, Inc. stock logo
PGEN
Precigen
190295.18 million156.15 millionOptionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20079.61 million69.00 millionOptionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.13 million22.85 millionNot Optionable

Recent News About These Companies

PureTech Health plc: PureTech Announces Board Change
PureTech CEO Bharatt Chowrira steps down
PureTech Health CEO Bharatt Chowrira Resigns
PureTech Announces Leadership Transition
PureTech Announces Board Change
Leerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Kodiak Sciences stock logo

Kodiak Sciences NASDAQ:KOD

$8.62 +0.10 (+1.17%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$8.62 0.00 (0.00%)
As of 08/13/2025 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Precigen stock logo

Precigen NASDAQ:PGEN

$1.91 +0.11 (+6.11%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$1.94 +0.03 (+1.31%)
As of 08/13/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$1.61 -0.03 (-1.83%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$1.63 +0.02 (+1.18%)
As of 08/13/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$17.74 +0.25 (+1.40%)
As of 08/13/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.